1)Maningding E, Kermani TA:Mimics of vasculitis. Rheumatology(Oxford)60:34-47, 2021
2)Landry ML:Parvovirus B19. Microbiol Spectr 4, 2016
3)Young NS, Brown KE:Parvovirus B19. N Engl J Med 350:586-597, 2004
4)Broliden K, et al:Clinical aspects of parvovirus B19 infection. J Intern Med 260:285-304, 2006
5)Mage V, et al:Different patterns of skin manifestations associated with parvovirus B19 primary infection in adults. J Am Acad Dermatol 71:62-69, 2014
6)Sajjan VV, et al:Livedo reticularis;A review of the literature. Indian Dermatol Online J 6:315-321, 2015;
7)Waldman M, Kopp JB:Parvovirus B19 and the kidney. Clin J Am Soc Nephrol 2(suppl 1):S47-56, 2007
8)Vassilopoulos D, Calabrese LH:Virally associated arthritis 2008;Clinical, epidemiologic, and pathophysiologic considerations. Arthritis Res Ther 10:215, 2008
9)Jennette JC, et al:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 65:1-11, 2013
10)Kitching AR, et al:ANCA-associated vasculitis. Nat Rev Dis Primers 6:71, 2020
11)Kallenberg CG:The diagnosis and classification of microscopic polyangiitis. J Autoimmun 48-49:90-93, 2014
12)Wallace ZS, Miloslavsky EM:Management of ANCA associated vasculitis. BMJ 368:m421, 2020
13)Suppiah R, et al;DCVAS Study Group:2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis Rheumatol 74:400-406, 2022
14)Collins MP, Periquet MI:Isolated vasculitis of the peripheral nervous system. Clin Exp Rheumatol 26(Suppl 49):S118-130, 2008